Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Altimmune, Inc. ALT

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$41,000
▲ 105.0% YoY
$-88.1M
$-67.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 41,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -88.1
10M20M-40M-80M
201020132016201920222025
Compound annual growth
−65.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −65.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -230461.0% · Net ·
50000%100000%-200000%-400000%
201020172025
ROE
FY2025 · ROE -50.6%
-100%-200%
201020172025
Three returns, three denominators.

Each USD of equity lost 51 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -67.5
-40M-80M
201020172025

Total assetsUSD 279.9M
EquityUSD 224.9M
CashUSD 43.8M
Gross debtUSD 34.3M
Net debtUSD -9.5M
Current ratio18.55×

The company holds more cash than debt.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ALT, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.0−0.00.00.00.00.00.00.0◌◌◌◌0.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0◌◌−0.0◌−0.0−0.0−0.0−0.00.00.00.00.00.0◌◌
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1◌−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌−0.0−0.0
EPS, diluted $−1.00−1.34−1.66−1.81−2.35−1.91−1.60−15.16−118.91−1.66−0.05−0.17−0.23−0.10−0.08−1.08
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−50.6−59.9−46.6−44.1−45.7−36.1−43.7−89.3−129.7−29.4−11.2−77.7−123.3−35.7−27.1−285.4
Shares out B0.110.070.070.050.040.040.020.010.020.070.060.060.050.050.050.05

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image